David W. Gryska - 21 Nov 2022 Form 4 Insider Report for AERIE PHARMACEUTICALS INC

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 21 Nov 2022
Net transaction value: -$375,227
SEC form: 4
Accepted by SEC: 21 Nov 2022, 15:43:42 UTC
Prior SEC filing: 15 Nov 2022
Next SEC filing: 12 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ John W. LaRocca, Attorney-in-Fact for David W. Gryska

Key filing fact

David W. Gryska filed Form 4 for AERIE PHARMACEUTICALS INC on 21 Nov 2022.

Key facts

This page summarizes David W. Gryska's Form 4 filing for AERIE PHARMACEUTICALS INC.
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 21 Nov 2022, 15:43.

Change

Previous filing in this sequence was filed on 15 Nov 2022.
Current net transaction value: -$375,227.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AERI transaction

Common Stock

Disposed to Issuer

Transaction value: $175,299
Shares: -11,495
Change %: -100%
Price: $15.25
Shares after: 0
Date: 21 Nov 2022
Ownership: Direct
Footnotes: F1

AERI transaction

Common Stock

Disposed to Issuer

Transaction value: $30,439
Shares: -1,996
Change %: -100%
Price: $15.25
Shares after: 0
Date: 21 Nov 2022
Ownership: By the Gryska Family Trust
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AERI transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $15,444
Shares: -7,800
Change %: -100%
Price: $1.98^*
Shares after: 0
Date: 21 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,800
Exercise price: $13.27
Footnotes: F2

AERI transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value: $154,046
Shares: -16,854
Change %: -100%
Price: $9.14
Shares after: 0
Date: 21 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,854
Exercise price: $6.11
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

David W. Gryska is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

Each of the reported shares of common stock of the Company (each a "Share" or, collectively, the "Shares"), including any Shares of restricted stock, was, at the Effective Time (defined below), cancelled and converted into the right to receive $15.25 in cash (the "Merger Consideration") without interest and subject to any applicable withholding taxes.

Footnote F2

Each stock option with a per Share exercise price that is less than the Merger Consideration was, at the Effective Time, cancelled in exchange for a cash payment equal to, for each Share underlying the stock option (without regard to vesting), the excess of the Merger Consideration over the exercise price payable per Share underlying such stock option. Any stock options with a per Share exercise price that was more than the Merger Consideration were cancelled for no consideration.

SEC remarks

This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of August 22, 2022, by and among Aerie Pharmaceuticals, Inc. (the "Company"), Alcon Research, LLC (the "Parent"), and Lyon Merger Sub, Inc., a copy of which is filed as Exhibit 2.1 to the Company's Form 8-K filed with the SEC on August 23, 2022, pursuant to which the Company became a wholly owned subsidiary of Parent on November 21, 2022 (the "Effective Time").